Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Vascular Cell Adhesion Molecule 1 (VCAM1) antibody (FITC)
|Synonyms||CD106, MGC99561, INCAM-100, DKFZp779G2333, Vcam-1, VCAM1B, MGC108734, VCAM1, fi76d06, wu:fi76d06, zgc:158875, VCAM-1, DKFZp469N1820|
Alternatives Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
|4 references available|
|Quantity||100 tests/ml (Variants)|
|Price||789.36 $ Plus shipping costs $45.00|
|Description||Vascular cell adhesion protein 1 also known as vascular cell adhesion molecule 1 (VCAM-1) or CD106 (Cluster of Differentiation 106) is a protein that in humans is encoded by the VCAM1 gene. VCAM-1 functions as a cell adhesion molecule. The CD106 antigen (vascular cell adhesion molecule, VCAM-1) is expressed primarily on vascular endothelium but has also been identified on follicular and other lymphoid tissue dendritic cells, some macrophages, bone marrow stromal cells and non-vascular cell populations within joints, kidney, muscle, heart, placenta and brain. Expression on endothelial cells as well as many other cells is induced by inflammatory stimuli and cytokines. Soluble CD106 released from activated endothelial cells can be detected in blood. CD106 antigen binds the integrins a4b1 (CD49d/CD29, VLA-4) and a4b7. VLA-4 is the dominant ligand in cells expressing both integrins. Endothelial CD106 contributes to the extravasation of lymphocytes, monocytes, basophils and eosinophils (but not neutrophils) from blood vessels, especially at sites of inflammation. The VLA-4 interaction can mediate both the initial tethering and rolling of lymphocytes on endothelium as well as their subsequent arrest and firm adhesion. CD106 expression on non-vascular tissues is thought to play a role in the interaction of hematopoietic progenitors with bone marrow stromal cells, B cell binding to follicular dendritic cells, co-stimulation of T cells and embryonic development.|
|Characteristics||CD markers,Cell adhesion|
|Specificity||Clone B-K9 produces mouse IgG1 immunoglobulins directed against a 110 kD protein known as human CD106. It reacts with approximately 15% of peripheral lymphocytes and between 30-90% activated HUVEC.|
B-K9 is a mouse monoclonal IgG1 antibody raised against CD106.
|Application Notes||CD106, clone B-K9, can be applied in flow cytometry for analysis of blood and bone marrow samples or in immunohistochemistry using cytospots or frozen tissue sections. Optimal antibody dilution should be determined by titration.|
|Buffer||0.01 M sodium phosphate, 0.15 M NaCl, 0.2% BSA, 0.09% sodium azide, pH 7.3.|
|Storage||Store at 4°C.|
|Research Area||CD Antigens, Surface Receptors of Immune Cells|
|Restrictions||For Research Use only|
Carlos, Harlan: "Leukocyte-endothelial adhesion molecules." in: Blood, Vol. 84, Issue 7, pp. 2068-101, 1994 (PubMed).
Berlin, Berg, Briskin et al.: "Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1." in: Cell, Vol. 74, Issue 1, pp. 185-95, 1993 (PubMed).
Bevilacqua: "Endothelial-leukocyte adhesion molecules." in: Annual review of immunology, Vol. 11, Issue 4, pp. 767-804, 1993 (PubMed).
Butcher, Picker: "Lymphocyte homing and homeostasis." in: Science (New York, N.Y.), Vol. 272, Issue 5258, pp. 60-6, 1996 (PubMed).